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Abstract
Background: Experts suggest a short duration of antibiotic therapy (DOT) in responding patients
with community-acquired pneumonia (CAP). The aim of this study was to evaluate clinical out-
comes after hospital discharge among patients treated with short-course antibiotic therapy (SCT)
vs. long-course antibiotic therapy (LCT) for CAP.
Methods: A secondary analysis of the Community-Acquired Pneumonia Organization (CAPO)
database from January 2007 to June 2013 was performed, including hospitalized CAP patients
who reached clinical stability within 5 days. Two groups were identified: patients who were treated
with antibiotic therapy for a total duration of 5 days or less (SCT Group) vs. longer than 5 days
(LCT Group). Rehospitalization and mortality were evaluated at 30 days after discharge.
Results: 1,849 patients were enrolled (58% males; median age: 65 years), 179 (10%) were
included in the SCT and 1,670 (90%) in the LTC group. Median DOT was 5 days in the SCT and10
days in the LTC group, p<0.001. At 30-day follow-up, there were no deaths in the SCT group, while
8 patients (0.7%) died in the LCT group, p=0.488. A total of 13 (11%) rehospitalizations were
detected at 30 days after discharge in the SCT group vs. 132 (11%) in the LCT group, p=0.879.
Once adjusted for several confounders, a short duration of antibiotic therapy was not associated
to either adverse outcomes (OR: 1.04; 95% CI: 0.54-1.99; p=0.912).
Conclusions: A duration of antibiotic therapy of ≤ 5 days does not adversely impact clinical
outcomes at 30-days after discharge compared to > 5 days in patients who reached early clinical
stability.
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1 Introduction
Community-acquired pneumonia (CAP) is the leading cause of
death from infectious diseases in most western countries1. One
of the options to reduce morbidity and mortality in patients with
CAP is to optimize antibiotic usage2. Increasing evidence over
the last ten years has strengthened recommendations of guide-
lines concerning antibiotic selection, early initiation of therapy
and switch from intravenous to oral therapy3. However, the ap-
propriate duration of antimicrobial treatment remains a matter of
controversy.
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In clinical practice, a standard 10-14 day approach is still used
to decide duration of antibiotic therapy in CAP patients, although
guideline recommendations suggest a short duration of antibiotic
therapy for patients with an early clinical response4,5. Since most
CAP patients become clinically stable within 3-7 days from hos-
pital admission, the American Thoracic Society (ATS) guidelines
suggest that longer durations of therapy are rarely necessary5.
However, few studies have evaluated the individualized approach
targeted on each patient’s clinical response to treatment5–8. Ac-
cording to guidelines suggestions, it is conceivable that a short
duration (≤ 5 days) of antibiotic therapy in responding patients
should lead to similar long-term outcomes in comparison to those
treated for more than 5 days. In that sense, Uranga et al. pub-
lished a randomized clinical trial of duration of therapy (DOT) in
CAP subjects9. 312 patients were enrolled in the study. In the
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intervention group, treatment was at least 5 days, according to
clinical improvement. In the control group, duration of therapy
was according to physician decision. In the intervention group
DOT was 5 days versus 10 days in the control group. The authors
found no differences in pneumonia success rate at 10 or 30 days
after admission. However, the expected outcome could not be
proven.
In order to strengthen this hypothesis, we decided to evaluate
clinical outcomes after discharge among hospitalized patients
with CAP who reached clinical stability within 5 days after ad-
mission and received antibiotics for ≤ 5 days versus those who
received antibiotics for ≥ 5 days.
2 Methods
2.1 Study Design
A secondary analysis of the Community-Acquired Pneumonia Or-
ganization (CAPO) database was performed. The database con-
tains data retrospectively collected from 60 hospitals in over
30 countries, between January, 01 2007 to June, 30 2013 was
performed. In each participating center, primary investigators
selected adult nonconsecutively hospitalized patients diagnosed
with CAP. All data was collected on a case report form and trans-
ferred electronically to the CAPO coordinating center at the Uni-
versity of Louisville (Louisville, KY, USA). Discrepancies and in-
consistencies in the data were determined at the coordinating
center. After queries were clarified, cases were entered into the
electronic REDCap database. Local institutional review board ap-
proval was obtained for each study site.
2.2 Inclusion and exclusion criteria
Patients≥ 18 years of age and meeting the study definition of CAP
and who reached clinical stability within 5 days after admission
were included in this study. In order to investigate primarily the
duration of antibiotic therapy prescribed only for the episode of
CAP, patients who received antibiotic therapy for either <3 days
or >28 days were excluded from the statistical analysis. Patients
who died while receiving antibiotic therapy during hospitaliza-
tion, as well as those for whom the duration of antibiotic therapy
was missing from the database, were also excluded from the sta-
tistical analysis.
2.3 Study Definitions
CAP was defined as the presence of a new pulmonary infiltrate
on chest radiograph at the time of hospitalization associated with
at least one of the following: 1) new or increased cough; 2) an
abnormal temperature (<35.6◦C or >37.8◦C) or 3) an abnormal
serum leukocyte count (leukocytosis, left shift, or leukopenia de-
fined by local laboratory values)10.
Patients with healthcare-associated pneumonia (HCAP) (patients
who were hospitalized in an acute care hospital for two or more
days within 90 days of the infection; resided in a nursing home
or long-term care facility; received recent intravenous antibiotic
therapy, chemotherapy, or wound care within the past 30 days
of the current infection; or attended a hospital or hemodialysis
clinic) were also included in the study11.
Time to clinical stability (TCS) was calculated as the number of
days from the date of admission to the date the patient reached
clinical stability criteria. Clinical stability was defined as fol-
lows: 1) improved clinical signs (improved cough and shortness
of breath); 2) lack of fever for ≥ eight hours; 3) improving leuko-
cytosis (decreased ≥ 10% from the previous day); 4) tolerating
oral intake12. Criteria for clinical stability were evaluated daily
during the first 7 days of hospitalization. The day that these four
criteria were met was considered the day that patients reached
clinical stability.
Duration of antibiotic therapy was analyzed as total duration of
therapy and duration of intravenous and oral therapy. Total du-
ration of therapy was calculated by subtracting the day the last
antibiotic (either IV or oral) was discontinued from the day when
the first antibiotic (either IV or oral) was started.
2.4 Study Groups and Outcomes
Among patients who reached clinical stability during the first 5
days of hospitalization, two study groups were defined: patients
who were treated with antibiotic therapy for a total duration of
4-5 days for the short-course therapy group and those treated
with antibiotic therapy for 6-28 days for the long-course therapy
group.
Rehospitalization and mortality were evaluated as study out-
comes during the follow-up after hospital discharge and up to
day 30 after the initial diagnosis of pneumonia. Rehospitalization
was defined as readmission to the hospital for any reason dur-
ing follow-up. Mortality was defined as all-cause 30-day mortal-
ity during follow-up. Having either rehospitalization or mortality
during follow-up was also evaluated as study outcomes.
2.5 Statistical Analysis
All statistical analyses were performed using SPSS (version 18.0;
SPSS Inc., Chicago, IL, USA). Descriptive statistics were reported
at baseline, with continuous data expressed as a median (25-
75 interquartile range -IQR) and categorical data expressed as
counts. Patient characteristics were compared between groups.
Differences of continuous data between two groups were evalu-
ated by Mann-Whitney U test (two groups). Differences of cat-
egorical variables between two or more groups were analyzed
using the 2 test or Fisher’s exact test where appropriate. Potential
predictors of a combined adverse outcome that were considered
of clinical relevance were investigated with the multivariable bi-
nomial logistic regression analysis. A P-value <0.05 was consid-
ered statistically significant.
3 Results
3.1 Study Population
A total of 3,324 patients were enrolled during the study period
(male: 1,984; median age: 67 years), 1,475 were excluded
(Figure 1). The final study population of patients who reached
clinical stability within 5 days after hospital admission and were
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Fig. 1 Study flow diagram. CAP: community-acquired pneumonia; TCS: time to clinical stability; DOT: duration of treatment.
discharged alive accounted for 1,849 subjects. The median (IQR)
TCS in the study population was of 3 (2-4) days. A total of
179 patients (10%) belonged to short-course group, and 1,670
patients (90%) to long-course group. No significant differences
were found between the two study groups in terms of demograph-
ics, comorbidities, or severity of the disease on admission (Table
1). The median (IQR) TCS was 3 (1-4) days in the short-course
therapy group and 3 (2-4) days in the long-course therapy groups;
P=0.014. The median (IQR) duration of antibiotic therapy was
5 (4-5) days in the short group, and 10 (8-12) days in the long
group; P<0.001. (Table 2) Median (IQR) DOT among patients
undergoing empiric monotherapy was 9 (7-11) days vs. 10 (7-
12) days for those undergoing combination therapy; P<0.001.
The median (IQR) LOS in the entire study population was 7 (4-
10) days. Median (IQR) LOS was 5 (4-6) days in the short group
vs. 7 (5-10) days in the long group; P<0.001. DOT coincided
with LOS in 380 patients (20%). DOT was longer than LOS in
1,002 patients (55%) and shorter in 456 patients (25%).
3.2 Clinical Outcomes
No patient died during follow-up in the short-course group, while
8 patients (0.7%) died in the long-course group; P=0.488. A total
of 13 (11%) rehospitalizations were detected during follow-up in
the short group vs. 132 (11%) in the long group, P=0.879 (Table
2).
Either outcome during follow-up was detected in 153 patients
(12%) among the entire study population; 13 patients (11%) in
the short vs. 140 patients (12%) in the long group; P=0.970.
Demographics, severity of disease, clinical, laboratory, and radio-
logical findings with significant univariate association with either
outcome during follow-up in the study population are shown in
Table 3. The multivariable logistic regression model showed that
HCAP (Odds Ratio (OR): 2.13; 95% CI: 1.31-3.47, P=0.002), and
chronic obstructive pulmonary disease (COPD) (OR: 2.20; 95%
CI: 1.45-3.35; P<0.001) on admission were independent predic-
tors of adverse outcomes during follow-up. Once adjusted for sev-
eral confounders, a short duration of antibiotic therapy (5 days)
was not associated with either outcome (OR: 1.04; 95% CI: 0.54-
1.99; P=0.912).
4 Discussion
Our study shows that among hospitalized patients with CAP who
reached clinical stability within 5 days, and who received antibi-
otic therapy for 4 or 5 days had no significant differences in out-
comes compared to those who received antibiotics for >5 days.
Furthermore, adjusting for several confounders did not impact
clinical outcomes. SCT was associated in our study with a signifi-
cant reduction in LOS. From a clinical point of view, our findings
support using shorter durations for antibiotics. Our results could
help implementation of tailored protocols to determine antibiotic
discontinuation in clinical practice, which could then have a great
impact in reducing total antibiotic exposure, bacterial resistance
and costs. Our findings also support that an individualized strat-
egy, based on patients’ clinical stability, can be considered the
most comprehensive approach in determining the duration of an-
tibiotic therapy.
The interaction between the host, the pathogen, and antibiotic
factors characterize the clinical response in each single case of
CAP, and determines the time in which a patient reaches clini-
cal stability. At that point, the bacterial burden in the lung is
greatly decreased due to a combination of the patient’s immune
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Table 1 Baseline demographics, comorbidities, severity of the disease, clinical, laboratory and radiological findings on admission, microbiology and
antibiotic therapy data of the study population, according to the two study groups: short-course therapy, and standard-course therapy.
Characteristic Short-course therapy Long-course therapy P
n = 179 n = 1,670
Demographics, n. (%)
Male 94 (53) 974 (58) 0.135
Age, median (IQR) years 64 (46-79) 66 (49-79) 0.261
Health-care associated pneumonia 21 (12) 199 (12) 0.942
Comorbidities, n. (%)
Congestive heart failure 25 (14) 232 (14) 0.978
Active Coronary artery disease 15 (8.4) 140 (8.4) 0.999
Essential hypertension 57 (32) 525 (31) 0.911
Chronic obstructive pulmonary disease 39 (22) 365 (22) 0.983
Neurological disease 23 (13) 249 (15) 0.459
Diabetes mellitus 29 (16) 295 (18) 0.624
Cerebrovascular accident 25 (14) 182 (11) 0.216
Renal disease 20 (11) 129 (7.7) 0.107
Liver disease 9 (5) 99 (5.9) 0.625
Neoplastic disease 17 (9.5) 173 (10) 0.718
Severity on admission, n. (%)
Altered mental status 19 (11) 170 (10) 0.855
Admission to ICU 8 (4.5) 96 (5.7) 0.480
PSI Risk Class IV and V 81 (45) 846 (51) 0.169
CURB-65 score 4 and 5 6 (3.4) 69 (4.1) 0.615
Physical findings, median (IQR)
Systolic Blood Pressure 130 (113-146) 125 (110-142) 0.162
Diastolic Blood Pressure 75 (65-80) 70 (60-80) 0.050
Heart rate, bpm 93 (80-107) 98 (85-110) 0.005
Respiratory rate, bpm 20 (18-24) 22 (18-26) 0.008
Alteration of gas exchange* 60 (34) 678 (41) 0.066
Laboratory values
White blood cells count, cell 11,410 (8,000-16,000) 11,510 (8,000-15,800) 0.901
Arterial pH<7.35 3 (4.2) 52 (7.3) 0.324
Sodium <130 mmol/L 10 (6.1) 117 (7.2) 0.598
Hematocrit <30% 10 (5.7) 121 (7.5) 0.388
Blood urea nitrogen, mg/dL 16 (6-32) 23 (11-40) <0.001
Microbiology, n. (%)
Pathogen isolated 57 (32) 562 (34) 0.626
Mixed infection 4 (2.2) 47 (2.8) 0.653
Bacteremia 14 (14) 110 (9.1) 0.142
S. pneumoniae 15 (8.4) 257 (15.4) 0.012
MSSA 2 (1.1) 13 (0.8) 0.631
MRSA 3 (1.7) 16 (0.9) 0.606
H. influenzae 2 (1.1) 22 (1.3) 0.822
P. aeruginosa 1 (0.6) 6 (0.4) 0.680
M. catarrhalis 1 (0.6) 3 (0.2) 0.300
Legionella spp. 2 (1.1) 27 (1.6) 0.609
M. pneumoniae 2 (1.1) 17 (1.0) 0.900
K. pneumoniae 1 (0.6) 10 (0.6) 0.947
Antibiotic used, n. (%)
Ceftriaxone 70 (41) 734 (44) 0.483
Levofloxacin 44 (26) 502 (30) 0.127
Azithromycin 61 (34) 490 (29) 0.188
Clarithromycin 35 (20) 309 (19) 0.732
Cefotaxime 1 (0.6) 7 (0.4) 0.787
Amoxicillin/clavulanate 31 (17) 182 (11) 0.011
Ampicillin/Sulbactam 10 (5.6) 129 (7.7) 0.303
Monotherapy 63 (35) 523 (31) 0.289
Time from arrival to first antibiotic dose,
median (IQR) hours
4.5 (2.4-9.1) 4 (2.5-6.5) 0.556
Switched from intravenous to oral antibiotic 77 (43) 1161 (70) <0.001
N: number; IQR: 25-75 interquartile range; ICU: intensive care unit; PSI: pneumonia severity index; CXR: chest
radiograph; MSSA: methicillin-sensible S. aureus
response and the antibiotic activity. After a short time, the an-
tibiotic could be discontinued. It is reasonable to suspect that as
microorganisms are killed at the alveolar level, clinical improve-
ment occurs. There is evidence supporting the idea of rapid clear-
ance of pathogens from the lungs in pulmonary infections13–17.
Between 1940 and 1960, some authors described rapid defer-
vescence of pneumococcal pneumonia symptoms as early as 12
hours, with clinical cure after one to three days of therapy13,14.
More recently, Dunbar et al. demonstrated that 5 days of lev-
ofloxacin are as effective as 10 days in patients with CAP15. In
that way, El Moussaoui et al. showed that 3 days of amoxicillin
was as effective as 8 days in patients with pneumonia who reach
clinical stability by day 316. Similarly, animal models showed us
a rapid killing of microorganisms in the lung with adequate ther-
apy17. Clearly, the most important concern about a short course
treatment is the possibility of occurrence of complications and de-
layed clinical failure. However, in an earlier study by Halm et al.,
the authors demonstrated that if clinical stability is reached, the
occurrence of unfavorable outcome is less than 1% in patients
treated with standard duration of therapy18. These results are
confirmed by other groups19. All this information taken together
implies that in patients who reach clinical stability soon in the
course of pneumonia, it is safe to shorten therapy, and this idea
is supported by our results. It pointed out the need for a tailored
duration of therapy according clinical evolution.
Several research groups have previously shown a strong correla-
tion between defervescence of inflammatory response and favor-
able clinical outcomes20,21. In that sense, the inclusion of the
demonstration of decreased levels of Procalcitonin or C-reactive
protein (CRP) between day 1 and day 3 could help physicians to
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Table 2 Patients experiencing adverse clinical outcomes after discharge and up to day 30 after the initial diagnosis of pneumonia in the study
population, according to the two study groups.
Characteristic Short-course therapy Long-course therapy P
n = 179 n = 1,670
Mortality, n 0 8 (0.7%; 95% CI: 0.2%-1.2%) 0.488
Rehospitalization, n 13 (11%) 132 (11%) 0.879
Combined outcomes*, n 13 (11%) 140 (12%) 0.970
*: Either death for any cause or rehospitalization after discharge and up to day 30 after the initial diagnosis of pneumonia
Table 3 Demographics, severity of disease, clinical, laboratory, radiological findings with significant univariate association with adverse outcome
(either all-cause mortality or rehospitalization) after discharge and up to day 30 after the initial diagnosis of pneumonia in the study population.
Characteristic Neither mortality Either mortality P
nor rehospitalization or rehospitalization
n = 1,696 n = 153
Demographics
Age, median (IQR) years 63 (47-78) 69 (53-82) 0.002
Health-care associated pneumonia, n. (%) 116 (9.9) 38 (25) <0.001
Comorbidities, n. (%)
Active Coronary artery disease 99 (8.4) 21 (14) 0.031
Essential hypertension 385 (33) 68 (44) 0.004
Chronic obstructive pulmonary disease 241 (21) 54 (35) <0.001
Neurological disease 160 (14) 35 (23) 0.002
Neoplastic disease 92 (7.8) 22 (14) 0.006
Severity on admission, n. (%)
Altered mental status 100 (8.5) 27 (18) <0.001
Admission to ICU 52 (4.4) 12 (7.8) 0.063
PSI Risk Class IV and V 552 (47) 89 (58) 0.009
CURB-65 score 4 and 5 36 (3.1) 11 (7.2) 0.009
Laboratory values, median (IQR)
Creatinine, mg/dL 1.0 (0.9-1.3) 1.0 (0.9-1.6) 0.021
Hematocrit, % 39 (35-42) 38 (34-41) 0.031
Empiric antibiotic therapy, n. (%)
Monotherapy 388 (33) 60 (39) 0.126
Time from arrival to first antibiotic dose, me-
dian (IQR) hours
4 (2.5-6.5) 4 (2-7.5) 0.745
N: number; IQR: 25-75 interquartile range; ICU: intensive care unit; PSI: pneumonia severity index.
decide to shorten therapy. According to Menendez et al.20, de-
creased levels of CRP below 100 mg/dl by day 3, and represent-
ing more than a 50% reduction between day 1 to 3 may be the
clinical thresholds to shorten antibiotic therapy. In studies eval-
uating Procalcitonin, different safety cutoffs have been used and
several aspects should be taken into account when interpreting
this biomarker22.
Our study has several limitations. In view of its retrospective
design, neither selection biases nor other unapparent clinical in-
formation that could be important for clinical decision regarding
duration of antibiotic therapy can be excluded. For instance, in-
formation for patients developing a complication, prolonging an-
tibiotics despite achieving clinical stability are missing. Further-
more, the number of patients included in the SCT group might not
have been enough to detect a significant difference in outcomes
in comparison to patients in the LCT group. This study confirms
the results of Uranga et al.9, providing evidence of usual clin-
ical practice, beyond a controlled clinical trial. Our results are
strengthened by the large cohort of patients enrolled worldwide
without strict exclusion criteria and this increases the generaliz-
ability of our findings. Furthermore, we used clinical information
available in clinical practice to define a patient’s response to ther-
apy, which is used regularly by physicians and easy to define and
interpret. Future research should be focused on the usefulness of
biomarkers to determine clinical stability.
In conclusion, our data showed that among hospitalized patients
with CAP who reached clinical stability within five days after ad-
mission, similar clinical 30-day outcomes might be detected be-
tween patients treated with five days of antibiotics versus those
treated with more than five days.
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